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Purpose or Objective: Intensity modulated radiotherapy 
(IMRT), including helical Tomotherapy (HT), has been only 
recently introduced in the treatment of locally advanced 
rectal cancer (LARC) patients. We retrospectively assessed 
acute toxicity and efficacy of concomitant chemo-
radiotherapy (CRT) delivered with HT and daily image-guided 
RT (IGRT) for non metastatic LARC patients in 2 Swiss 
institutions. 
 
Material and Methods: We analyzed acute grade 3+ toxicity 
(CTC-AE v.4.0) and local control (LC) rates. Late toxicity 3+, 
Overall (OS), disease-free (DFS), and colostomy-free survival 
(CFS) were also studied and reported. Tumor Regression Rate 
(TRG) after CRT was scored using the Mandard score. 
Volumes were defined as follows: CTV1: rectum + 
mesorectum + internal iliac nodes + presacral nodes + 
obturatory nodes. In one of the 2 institutition, a CTV2 was 
also defined: rectal GTV + corresponding mesorectum (with a 
2-cm margin in the cranio-caudal direction) + nodal GTV (if 
N+ patients). Planning target volumes were obtained by 
adding 5-mm margin to the CTV (PTV1 and PTV2, 
respectively). PTV1 received 44-45 Gy (1.8-2 Gy/fraction), 
while PTV2 received a simultaneous integrated boost up to a 
total dose of 50 Gy (2 Gy/fr).  
 
Results: From 01.2010 to 01.2015, 118 patients were treated; 
35, 9, 61, 12 and 1 patients presented a stage II, IIIA, IIIB, IIIC 
and IVa, respectively. Median age was 65 years (range, 32-
85). All patients received concomitant CTX with 
fluoropyrimidine (i.v. or oral). After a median time of 53 days 
(range, 1-142), all patients received a radical surgery. Mean 
follow-up was 21 months (range: 1-62). No Grade 3 acute 
toxicity was observed. Acute grade 1-2 toxicity was observed 
in 22% of patients. Three-years LC, OS, DFS, and CFS rates 
were 95,2%, 82.4%, 83% and 69%, respectively. Median time 
to any progression for relapsing patients was 23 months 
(range: 5-66). At the time of analysis, 108 patients presented 
more than 4 months of followup and were considered 
evaluable for late toxicity. Data about late toxicity were not 
available for 48 patients, followed in other Institutions after 
RT-CT. Looking at the final 60 patients, only 2 of them 
patients presented a late G3 gastrointestinal toxicity (anal 
incontinence). Looking at 3-year LC, at univariate analysis, 
patients operated in the 66 days after the end of the 
treatment (98.8% vs 83.6%, Log-rank test: p = 0.022) and 
those without endovascular invasion at final pathology (98.6% 
vs 83.3%, p = 0.022) presented better LC rates. Concomitant 
boost did not improve 3-year LC, but increased the rate of 
TRG1 and TRG1-2 patients (Pearson's chi-squared test : p = 
0.002 and p = 0.04, repsectively). 
 
Conclusion: CRT delivered using HT and daily IGRT is safe 
and effective in the treatment of LARC patients. Longer 
followup time and prospective series are needed to confirm 
our results. Concomitant boost increase the rate of complete 
or nearly complete pathological response. The impact of TRG 
on the LC could probably assessed on after a longer followup 
time. 
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Purpose or Objective: To evaluate safety and feasibility of 
SIB-IMRT with VMAT combined with chemotherapy as 
exclusive treatment in patients with anal cancer. Early 
response is a secondary endpoint. 
 
Material and Methods: From November 2010 to June 2015, 
16 consecutive patients with histological diagnosis of anal 
squamous cells carcinoma underwent to chemoradiation in 
our center. Patients’ characteristics are described in Table 1. 
Radiation schedule consisted of 52-58 Gy in 2-Gy daily 
fractions to High Risk Volume (HR), 49.95-54 Gy to 
Intermediate Risk Volume (IR) and 45-48 Gy to Low Risk 
Volume. Daily dose fraction was around 1.65 and 1.75 for LR 
and IR respectively. One patient received a radiation boost 
up to 66 Gy after 60 days from the end of chemoradiation 
due to a poor objective response. HR, IR and LR delineation 
was performed according to AIRO guidelines published in 
2012 and reviewed in 2014. Organs at Risk (OAR) were: 
bladder, bilateral femoral heads and small bowel. All 
treatment plans were obtained with VMAT technique. SIB was 
calculate by Oncentra Inverse Planning System. In the first 3 
patients was performed a split course radiation schedule to 
reduce toxicity risk. Target objectives were minimum 
coverage by 95% isodose and maximum dose of 107% within 
the volume. OARs’ constraints were those suggested by AIRO 
guidelines (femoral heads: V52<10%; small bowel V45< 195cc; 
bladder: V60<50%). Median follow-up was 13 months (3-55). 
Concomitant chemotherapy is described in table 1.  
 
 
 
Acute Toxicity, according to RTOG criteria, was weekly 
recorded during radiotherapy course and monthly in the first 
three months of follow-up. 
 
Results: Target coverage and organ at risk sparing were 
optimal in all plans (fig1).  
 
 
During chemioradiation none of patients developed G3 
Gastroenteric toxicity (6 G1; 7 G2) and Genitourinary side 
effects were extremely rare (1 G1; 1 G2). Skin toxicity was 
the most important adverse event registered (8 G2; 4 G3). All 
chemotherapy schedule were well tolerated such the 
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incidence of hematologic toxicity was low (1 G1; 1G2). Early 
response evaluated by instrumental re-staging after 3 months 
from the end of treatment was encouraging, since 8 patients 
achieved complete response and 8 a partial response. Among 
the 6 patients with at least 2 years of follow up, 3 patient 
developed a progression disease (1 local relapse an 2 distant 
metastasis) and 1 patient died of disease after 3 years from 
treatment. The patient who underwent to radiation boost 
after chemoradiation developed anal stenosis which required 
a permanent colostomy. 
 
Conclusion: SIB with VMAT combined with chemotherapy is 
quite feasible in anal cancer treatment. It easily allows 
different dose delivering to target at different risk of disease 
involvement. Split course schedule has not be more used 
because of acceptable acute toxicity profile, which was 
confirmed in conventional fractionation. A larger patient 
number and a longer follow-up are required to confirm our 
data. 
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Purpose or Objective: Radiation treatment for rectal cancer 
is usually given in the prone position on a belly board with 
the aim to move the small bowel away from the treatment 
volume. In practice, this position is sometimes difficult to set 
up reproducibly and is poorly tolerated for some patients. 
With the increasing conformality and accuracy of using VMAT 
and cone beam CT (CBCT), we asked if there was any 
dosimetric advantage of treating rectal patients prone—it 
may be that patients can be better treated in the supine 
orientation. The two aims of this study are 1) to investigate 
setup reproducibility of rectal cancer patients treated in the 
prone and supine positions, and 2) to compare dose-volume 
histogram (DVH) metrics for the bladder and small bowel for 
both treatment positions. 
 
Material and Methods: Eighteen consecutive patients with 
rectal cancer who received neoadjuvant chemoradiation 
were selected for this study. 9 were treated supine and 9 in 
the prone position. Patients were prescribed a total dose of 
50.4 Gy in 1.8 Gy daily fractions according to institutional 
protocol and were planned with a VMAT posterior half arc. To 
determine setup reproducibility, weekly CBCTs were acquired 
and matched to bone. The CBCT-determined translational 
and rotational shifts were recorded. Clinically relevant dose-
volume histogram values were generated for the small bowel 
and bladder.  
 
Results: The CBCT-determined rotational setup error ranges 
for the prone position in pitch, roll, and yaw were [-3.6° 
4.7°], [-4.2° 3.2°], and [-1.4° 1.1°] respectively. For the 
supine position the corresponding ranges were [-4.8° 2.0°], [-
2.4° 1.3°], and [-1.0° 3.2°]. 7 patients exhibited >±3° 
rotational errors in the prone versus only 2 in the supine 
position, indicating better setup reproducibility in the supine 
position. Translational errors were generally <±1 cm in all 
directions for both positions. The small bowel V45 and mean 
dose for prone was 7.3±9.9% and 16.9±6.8 Gy (± values 
represent standard deviations) respectively; for supine the 
values were 6.8±7.6% and 19.6±6.4 Gy. The bladder V30 and 
mean dose for prone were 64.4±14.3% and 36.8±4.1 Gy 
respectively; for supine, these values were 68.7±18.5% and 
37.3±4.1Gy. 
 
Conclusion: There may be increased rotational instability in 
the prone position, but no apparent dosimetric advantage for 
small bowel sparing was observed. Rectal cancer patients 
who undergo neoadjuvant radiation using VMAT and CBCT 
may not need to be treated prone on a belly board. 
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Purpose or Objective: The present study analyses the 
correlation of pre-treatment (18)F-fluorodeoxyglucose 
Positron Emission Tomography/Computed Tomography (FDG-
PET/CT) standardized uptake value (SUV) and total lesion 
glycolysis (TLG) with tumour characteristics and clinical 
response in a series of rectal cancer patients treated with 
neoadjuvant chemo-radiotherapy.  
 
Material and Methods: Fifty-six patients were included in the 
present analysis. Pre-treatment PET maximum SUV (SUVmax), 
mean SUV and TLG of primary tumour were calculated for 
each patient. The total dose of pelvic radiotherapy was 45-
50.4 Gy, 1.8 Gy/fraction. Chemotherapy was delivered with 
capecitabina or 5-fluorouracil. Six to eight weeks after RT-
CT, 44 patients (78.6%) had anterior rectal resection and 12 
patients (21.4%) had abdominal pelvic resection (Miles).  
Tumor Regression Grade (TRG) (Mandard, 1994) was defined 
on surgical specimen. Complete regression (TRG1) was 
observed in 10/56 (17.9 %).The correlation between PET/CT 
results and histopathological data and tumour response was 
analyzed.  
 
Results: At the level of the primary tumour, SUVmax ranged 
from 4.17 and 54.06 (mean 22.46, median 18.96), SUV mean 
ranged from 6.22 and 32.64 (mean 13.42, median 11.09) and 
TLG ranged from 7.96 and 3158.23 (mean 350.21, median 
183.55). 
SUVmax (p=0.05) and TLG (p=0.002) significantly correlated 
with T-stage. Median SUVmax was significantly higher (p = 
0.05) for lesions with partial response (PR, 46/56, 82.1%) 
than for lesions with complete response (CR, 34/54, 17.9%). 
Median TLG was significantly higher (p=0.034) for lesions with 
partial response (PR, 45/54, 83.3%) than for lesions with 
complete response (CR, 9/54, 16.7%). 
SUVmean was not significantly correlated with T-stage 
(p=0.074). Median SUVmean was higher for lesions with 
partial response (PR, 45/54, 83.3%) than for lesions with 
complete response (CR, 9/54, 16.7%) but without statistical 
significance (p =0.18).  
 
Conclusion: Our data suggest that pre-treatment FDG-
PET/CT SUVmax and TLG are strongly associated with tumour 
primary tumour stage. Furthermore they correlate with 
prediction of tumour response after neoadjuvant treatment.  
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Purpose or Objective : The present study analyses the 
correlation of pre-treatment (18)F-fluorodeoxyglucose 
